Is Blue Water Biotech, Inc. overvalued or undervalued?

As of 29 August 2024, the valuation grade for Blue Water Biotech, Inc. has moved from does not qualify to risky. The company is currently considered overvalued. Key ratios include a Price to Book Value of 0.11, an EV to EBIT of -1.72, and an EV to EBITDA of -1.89, indicating significant financial distress.
In comparison to its peers, Blue Water Biotech's valuation metrics are less favorable, with Tonix Pharmaceuticals showing a P/E of -3.6690 and an EV to EBITDA of -1.7982. The company's recent stock performance has been poor, with a one-year return of -34.92%, contrasting sharply with the S&P 500's return of 10.26% over the same period, further reinforcing the perception of overvaluation.